Ze Chen

机构：Zhejiang A & F University, Chinese Academy of Medical Sciences & Peking Union Medical College, Jiangsu T-mab BioPharma (China), Innovative Clinical Research, Virginia Innovation Partnership Corporation, Xiyuan Hospital · ORCID：0000-0003-4717-0747

发表论文 150 篇 · 总被引 3300 次 · h-index 32

代表论文

• IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy (2021 · Biomaterials · 被引 124)
• Nanoengineered CAR‐T Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermal‐Remodeling Strategy (2021 · Small · 被引 105)
• MiR-133a-3p/Sirt1 epigenetic programming mediates hypercholesterolemia susceptibility in female offspring induced by prenatal dexamethasone exposure (2022 · Biochemical Pharmacology · 被引 24)
• Glucocorticoids and intrauterine programming of nonalcoholic fatty liver disease (2023 · Metabolism · 被引 18)
• Smart eutectogel with antibacterial activity for efficiently treating multidrug resistant infection, real-time monitoring and diabetic wound repair (2025 · Chemical Engineering Journal · 被引 16)
• Tofacitinib prevents depressive-like behaviors through decreased hippocampal microgliosis and increased BDNF levels in both LPS-induced and CSDS-induced mice (2024 · Acta Pharmacologica Sinica · 被引 14)